company
Fagron Compounding Services
Jurisdiction: US
FDA Warning Letter timeline
V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.
- fda_recall · drug_recall2026-04-15Fagron Compounding Services — Class II recall: norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fag…
- fda_recall · drug_recall2026-04-15Fagron Compounding Services — Class II recall: Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagr…
- fda_recall · drug_recall2026-04-15Fagron Compounding Services — Class II recall: norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fa…
- fda_recall · drug_recall2026-04-15Fagron Compounding Services — Class II recall: Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, F…
- fda_recall · drug_recall2026-04-15Fagron Compounding Services — Class II recall: Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP,…
- fda_483 · inspection_citation2025-08-08Fagron Compounding Services -- FDA 483: 3 observations (2025-08-08)
Frequently asked questions
- How many FDA warning letters has Fagron Compounding Services received?
- Argus HQ has not recorded an FDA warning letter for Fagron Compounding Services in our current dataset.
- What FDA recalls has Fagron Compounding Services issued?
- Argus HQ has recorded 5 FDA recalls tied to Fagron Compounding Services.
- Is Fagron Compounding Services FDA compliant?
- Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 0 warning letters, 5 recalls, and 0 approval records for Fagron Compounding Services. Review the linked FDA source records directly before drawing a compliance conclusion.
Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.